Peptide-coated Conditionally Replicating Adenovirus complex (PeptiCRAd) (PeptiCRAd)

The Peptide-coated Conditionally Replicating Adenovirus (PeptiCRAd) complex is a therapeutic platform that integrates oncolytic virotherapy with peptide-based vaccination to stimulate a comprehensive anti-tumor immune response [1]. The system utilizes a conditionally replicating adenovirus (CRAd) as an active scaffold, which is non-covalently coated with tumor-specific MHC-I or MHC-II restricted peptides [2]. Upon administration, the adenoviral components serve as a potent immunological adjuvant by activating Pattern Recognition Receptors (PRRs), such as Toll-like receptor 9 (TLR9), which triggers the maturation of dendritic cells and the secretion of pro-inflammatory cytokines [1, 3]. Simultaneously, the associated peptides are internalized and presented by these activated antigen-presenting cells, leading to the priming and expansion of tumor-specific CD8+ and CD4+ T cells [2]. This dual mechanism is designed to transform the immunosuppressive tumor microenvironment into an immunologically hot state, facilitating systemic destruction of both primary and metastatic lesions [3]. (Sources: [1] Capasso et al., OncoImmunology, 2016; [2] Ylosmaki et al., Molecular Therapy, 2018; [3] Valo Therapeutics, valotx.com)

Other names

PeptiCRAd platformPeptiCRAd technologyPeptide-coated CRAdPeptide-coated oncolytic adenovirus

Activation of innate immunity via Pattern Recognition Receptors (PRRs) such as TLR9 by adenoviral components, combined with the induction of adaptive immunity through MHC-mediated presentation of tumor-specific peptides coated on the viral capsid [1, 2].